The Spravato® treatment schedule follows a structured, FDA-approved timeline that balances rapid symptom relief with ongoing safety monitoring. Treatment begins with an induction phase lasting four weeks. During this phase, Spravato® (esketamine) is administered twice weekly under direct medical supervision in a certified healthcare setting.
Each session includes a pre-treatment assessment, intranasal administration, and a mandatory post-dose observation period of at least 2 hours to monitor for potential side effects, such as dissociation, sedation, or transient increases in blood pressure. The goal of the induction phase is to stabilize acute depressive symptoms, particularly in individuals with treatment-resistant depression.
Following induction, patients transition to a maintenance phase, with the frequency adjusted based on clinical response. During weeks five through eight, treatment is typically reduced to once weekly. After week nine and beyond, dosing is often spaced to once every one to two weeks, depending on symptom improvement and psychiatric evaluation.
The FDA-approved schedule allows flexibility within this framework to individualize care while maintaining adherence to REMS (Risk Evaluation and Mitigation Strategy) safety requirements. Ongoing psychiatric oversight ensures that treatment frequency is optimized to sustain symptom remission after Spravato® treatment while minimizing unnecessary exposure.
What Is the Standard Spravato® Treatment Schedule for Depression?
The standard Spravato® treatment schedule for depression follows the FDA-approved protocol established for adults with treatment-resistant depression or major depressive disorder with suicidal thoughts or behaviors. Spravato® treatment for depression begins with a four-week induction phase, during which Spravato® is administered twice weekly in a certified healthcare setting under the REMS program. Each visit includes pre-dose clinical assessment, intranasal administration of the medication, and a minimum two-hour post-dose monitoring period to evaluate blood pressure, sedation, and dissociative symptoms.
After the initial four weeks, patients transition into a maintenance phase. During weeks five through eight, treatment is typically reduced to once weekly. Beginning in week nine and continuing thereafter, dosing is generally spaced once every one to two weeks, depending on the individual’s clinical response and symptom stability.
The Spravato® treatment schedule is designed to provide rapid symptom reduction during the acute phase while gradually tapering frequency to sustain improvement. Ongoing psychiatric evaluation determines whether frequency adjustments are needed to maintain remission or prevent relapse.
How Often Are Spravato® Treatments Given During Induction?
During the initial phase of care, Spravato® is administered on a structured schedule designed to stabilize depressive symptoms while ensuring patient safety rapidly. The treatment schedule generally follows this timeline:
- Twice per week for four weeks: The FDA-approved induction phase consists of two treatment sessions per week over a four-week period (a total of eight sessions).
- In-clinic administration only: Each dose is given in a certified healthcare setting under the REMS program to ensure appropriate monitoring.
- At least 48 hours between sessions: Treatments are typically spaced several days apart (e.g., Monday/Thursday) to allow for clinical assessment and recovery between doses.
- Two-hour post-dose monitoring: After each session, patients remain under observation for a minimum of two hours to monitor blood pressure, sedation, and dissociative effects.
- Concurrent oral antidepressant: Spravato® is prescribed alongside a daily oral antidepressant as part of the FDA-approved treatment protocol.
Mental Health Treatment That Works
Call 949-625-0564What our customers are saying
How Long Does a Typical Spravato® Treatment Program Last?
The duration of a Spravato® treatment program varies based on individual response, but it follows a structured FDA-approved framework with both acute and maintenance phases. The duration of the program often follows this schedule:
- Induction Phase (First 4 Weeks): Twice-weekly treatments for four weeks to address acute depressive symptoms.
- Early Maintenance Phase (Weeks 5–8): Treatment frequency typically decreases to once per week, depending on clinical response.
- Ongoing Maintenance (Week 9 and Beyond): Sessions are generally scheduled once every one to two weeks based on symptom stability and psychiatric evaluation.
- Individualized Duration: There is no fixed end date; some patients continue maintenance treatment for several months or longer if clinically indicated.
- Regular Reassessment: Ongoing psychiatric monitoring determines whether to continue, adjust frequency, or discontinue treatment to prevent relapse while minimizing unnecessary exposure.
Can a Spravato® Treatment Schedule Be Adjusted Based on Patient Response?
Yes. While the Spravato® treatment schedule follows a structured FDA-approved framework, it is intentionally designed to allow clinical flexibility during the maintenance phase based on patient response.
During the initial four-week induction phase, treatments are administered twice weekly and generally remain fixed to achieve therapeutic stabilization. After this period, the dosing frequency may be adjusted based on symptom improvement, side-effect profile, functional recovery, and overall psychiatric assessment. For example, if a patient demonstrates sustained remission, sessions may be spaced every two weeks.
On the other hand, if symptoms begin to reemerge, frequency may be temporarily increased to once weekly. Any adjustments must remain within FDA-approved parameters and REMS safety requirements, including in-clinic administration and post-dose monitoring. Ongoing psychiatric evaluation ensures that treatment intensity aligns with clinical need while prioritizing safety and long-term symptom management.
Key Takeaways on Spravato® Treatment Schedule
- Spravato® follows a clearly defined schedule that includes an induction phase and a maintenance phase to balance rapid symptom relief with long-term stabilization.
- During the first four weeks, patients receive treatment twice per week to address acute depressive symptoms and establish a therapeutic response.
- After induction, treatment typically decreases to once weekly (weeks 5–8) and then once every one to two weeks beginning at week 9, depending on symptom stability.
- There is no universal endpoint; treatment length and frequency are adjusted based on clinical response, remission status, and relapse risk.
- All doses are administered in a certified healthcare setting under the REMS program, with mandatory post-treatment observation and ongoing psychiatric oversight.
The FDA-approved Spravato® treatment schedules implement safe, well-structured care pathways to ensure the best possible outcomes for patients. If you’re interested in learning more about how Moment of Clarity adheres to these proven clinical protocols and provides comprehensive support throughout the treatment process, or how to pay for Spravato® without insurance, please call us at 949-625-0564 to access evidence-based care tailored to your individual needs.
Resources
- McGovern Medical School – FDA Expands Approval of Intranasal Esketamine Therapy (Spravato®)
- National Institutes of Health – First FDA-Approved Prescription Nasal Spray for Treatment-Resistant Depression
- NPR – FDA allows standalone use of nasal spray antidepressant Spravato® (esketamine)
